Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation

Blood

Volumn 95, Issue 7, 2000, Pages 2240-2245

  Broers, Annoek E C ^b   Van Der Holt, Ron ^b   Van Esser, Joost W J ^b   Gratama, Jan Willem ^b   Henzen Logmans, Sonja ^b   Kuenen Boumeester, Vibeke ^b   Löwenberg, Bob ^b   Cornelissen, Jan J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR;

ARTICLE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; HUMAN; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; OUTCOMES RESEARCH; PATIENT MONITORING; PRIORITY JOURNAL; RISK FACTOR; STEM CELL TRANSPLANTATION; SURVIVAL; VIRUS REACTIVATION;

EID: 0034176751     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.7.2240.007k08_2240_2245     Document Type: Article

References (36)

1. Meyers JD, Flournoy N, Thomas E. Risk factors for cytomegalovirus infection after human bone marrow transplantation. J Infect Dis. 1986;153: 478.
2. Zaia JA. Cytomegalovirus infection. In: Forman SJ, Blume KG, Thomas ES, eds. Bone Marrow Transplantation. Boston, MA: Blackwell Scientific Publications; 1994:376.
3. Meyers JD, Ljungman P, Fisher LD. Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation: importance of cytomegalovirus viremia. J Infect Dis. 1990; 162:373.
4. Emanuel E, Cunningham I, Jules-Elysee K, et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med. 1988;109:777.
5. Ljungman P, Engelhard D, Link H, et al. Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: experience of the European Bone Marrow Transplant Group. Clin Infect Dis. 1992;14: 831.
6. Reed EC, Bowden RA, Dandliker PA, Lilleby KE, Meyers JD. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med. 1988; 109:783.
7. Winston DJ, Ho WG, Bartoni K, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Ann Intern Med. 1993;118:179.
8. Goodrich JM, Bowden RA, Fisher L, Keller C, Schock G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med. 1993;118: 173.
9. Prentice HG, Kho P. Clinical strategies for the management of cytomegalovirus infection and disease in allogeneic bone marrow transplant. Bone Marrow Transplant. 1997;19:135.
10. Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. N Engl J Med. 1991; 324:1005.
11. Goodrich JM, Mori M, Gleaves CA, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med. 1991;325:1601.
12. Boeckh M, Gooley TH, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood. 1996;88:4063.
13. Einsele H, Ehninger H, Hebart H, et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood. 1995;86:2815.
14. Verdonck LF, Dekker AW, Rozenberg-Arska M, Van den Hoek MR. A risk-adapted approach with a short course of ganciclovir to prevent cytomegalovirus (CMV) pneumonia in CMV-seropositive recipients of allogeneic bone marrow transplants. Clin Infect Dis. 1997;24:901.
15. Bacigalupo A, Tedone E, Soracco M, et al. CMV-antigenemia after allogeneic bone marrow transplantation: correlation of CMV antigen positive cell numbers with transplant related mortality. Bone Marrow Transplant. 1995;16:155.
16. Bacigalupo A, Tedone E, Sanna MA, et al. CMV infections following allogeneic BMT: risk factors, early treatment and correlation with transplant related mortality. Hematologica. 1997;77:507.
17. Van der Bij W, Torensma R. Van Son WJ, et al. Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leukocytes. J Med Virol. 1988;25:179.
18. Kuenen-Boumeester V, Van Loenen P, De Bruijn EMCA, Henzen-Logmans SC. Quality control of immunocytocnemical staining of efflusions using a standardized method of cell processing. Acta Cytol. 1996;40:475.
19. Salzberger B, Bowden RA, Hackman RC, Davis Ch, Boeckh M. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome. Blood. 1997;90:2502.
20. Boström L, Ringden O, Sundberg B, Linde A, Tonnemar J, Nilsson B. Pre-transplant herpes virus serology and graft-versus-host disease. Transplantation. 1988;46:548.
21. Boström L, Ringden O, Gratama JW, Jacobsen N, Zawwn F, Nilsson B, for the Leukaemia Working Party of the European Group for Bone Marrow Transplantation. The impact of pre-transplant herpes virus serology on acute and chronic graft-versus-host disease. Transplant Proc. 1990;22: 206.
22. Lönnqvist B, Ringden O, Wahren B, Gahrton G, Lundgren G. Cytomegalovirus infection associated with and preceding chronic graft-versus-host disease. Transplantation. 1984;38:465.
23. Jacobsen N, Anderson HK, Skinhoj P, et al. Correlation between donor CMV immunity and chronic GVHD after allogeneic bone marrow transplantation. Scand J Haematol. 1986;36:499.
24. Gratama JW, Fibbe WE, Naipal AMIH, et al. Cytomegalovirus immunity and T-lymphocytes in bone marrow donors and acute GVHD. Bone Marrow Transplant. 1986;1:141.
25. Gratama JW, Zwaan FE, Stijnen T, et al. Herpes virus immunity and acute graft-versus-host disease. Lancet. 1987;1:471.
26. Grundy JE, Shanley JE, Shearer GM. Augmentation of graft-versus-host reaction by cytomegalovirus infection resulting in interstitial pneumonitis. Transplantation. 1985;39:548.
27. Hendrikx MGS, Beuken E, Slobbe RL, Bruggeman CA. Detection and sequence analysis of the major immediate early and PP150 gene of latent human cytomegalovirus in spleen, liver and kidney tissues of trauma victims. J Med Virol. 1996; 50:193.
28. Grefte A, Van der Giessen M, Van Son W, The TH. Circulating cytomegalovirus (CMV)-infected endothelial cells in patients with an active CMV infection. J Infect Dis. 1993;167:270.
29. Lichtman A, Krenger W, Ferrara JLM. Cytokine networks. In: Ferrara JLM, Deeg HJ, Burakotf SJ, eds. Graft-versus-Host Disease. New York, NY: M. Dekker; 1997.
30. Verdonck LF, Dekker AW, De Gast GC, van Kempen ML, Lokhorst HM, Nieuwenhuis HK. Allogeneic bone marrow transplantation with a fixed low number of T-cells in the marrow graft. Blood. 1994;83:3090.
31. Prentice HG, Gluckman E, Powles RP, et al. The impact of long-term acyclovir on cytomegalovirus infection and survival in allogeneic bone marrow transplantation. Lancet. 1994;343:749.
32. Hebart H, Kanz L, Jahn G, Einsele H. Management of cytomegalovirus infection after solid-organ or stem cell transplantation. Drugs. 1998; 55:59.
33. Greenberg PD, Reusser P, Goodrich JM, Riddel SR. Development of a treatment regimen for human cytomegalovirus (CMV) infection in bone marrow transplantation recipients by adoptive transfer of donor-derived CMV-specific T-cell clones expanded in vitro. Ann N Y Acad Sci. 1991;636:184.
34. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T-cell. Science. 1992;257:238.
35. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333:1038.
36. Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood. 1991;78:1373.